LifeScience Biologics
Innovent Biologics Receives FDA Fast Track Designation for PD-1/IL-2α Bispecific Antibody in Advanced Melanoma Treatment
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
September 04, 2024 | News
Inside Asia-Pacific’s Cell and Gene Therapy Evolution: A Conversation with Raymond Chow, VP of Commercial, APAC at Cytiva
In an interaction with BioPharma APAC, Raymond Chow, Vice President of Commercial for Asia-Pacific at Cytiva, shares his insights on the rapidly evolving l...
September 02, 2024 | Interaction
Sanyou Biopharmaceuticals Introduces Comprehensive Monkeypox Product Line Featuring Antigens, Monoclonal Antibodies, and Overexpression Cell Lines
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of a comprehensive product line targeting monkeypox, which includes antigens, monoclona...
September 02, 2024 | News
Jacobio Pharma Grants China Rights for KRAS G12C and SHP2 Inhibitors to Shanghai Allist in Landmark Deal
Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted the China ...
September 02, 2024 | News
UTime Signs NDA for Strategic Acquisition of Bowen Therapeutics Lab to Boost Global Vaccine Development
UTime Limited has officially announced the signing of a non-disclosure agreement (the "NDA") with Bowen Therapeutics Inc ("Bowen Therapeutics") for th...
August 29, 2024 | News
LOTTE Holdings Launches New CVC to Propel Innovations in Biopharmaceuticals and Next-Generation Modalities
LOTTE Holdings Co., Ltd. ("LOTTE Holdings") is pleased to announce the establishment of a new Healthcare and Biopharmaceutical Corporate Venture Capital ("...
August 29, 2024 | News
Mabwell Receives NMPA Approval to Initiate Phase III Study of 9MW2821 in Recurrent or Metastatic Cervical Cancer
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (C...
August 26, 2024 | News
CanariaBio Completes Enrollment for Phase 2 Study of Oregovomab with Chemotherapy in Advanced Ovarian Cancer
CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study ...
August 26, 2024 | News
Yipurun's Corina System Receives Approval in China for Treating Moderate-to-Severe Intrauterine Adhesions
Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval i...
August 26, 2024 | News
Allozymes Partners with Adisseo to Transform Animal Feed Production with Innovative Bioprocesses
Allozymes, a leading innovator in enzyme discovery and engineering, announces a strategic partnership with Adisseo, one of the world's leading animal nutri...
August 20, 2024 | News
CARsgen Therapeutics Completes Enrollment in Pivotal Phase II Trial of Satri-Cel for Advanced Gastric Cancer in China
CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...
August 20, 2024 | News
Astellas Pharma Gains NMPA Approval for PADCEV™ in China to Treat Advanced Urothelial Cancer
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that the Center for Drug Evaluation (CDE) of C...
August 20, 2024 | News
Driving Healthcare Innovation in Asia: Rehan Saghir of ZP Therapeutics on Pioneering Drug Commercialization and Overcoming Regional Challenges
In an exclusive interview with BioPharma APAC, Rehan Saghir, Executive Vice President of ZP Therapeutics, Zuellig Pharma shares his expert insights...
August 20, 2024 | News
Boston Immune Technologies and Therapeutics Secures Strategic Agreement with Otsuka's MSRD and $4M NIH/NCI Grant for Advancing Antibody Development
Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical stage developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist...
August 19, 2024 | News
Most Read
- Bridging the Vision Gap: Roche’s Ahmed Elhusseiny on Eye Health Priorities in Asia Pacific
- How Merck’s India-Based Navi Mumbai Centre is Reimagining Formulation Science for the Global Generics Market
- Advancing Cell & Gene Therapy in APJ: How Thermo Fisher Enables Breakthrough Innovation
- AstraZeneca’s Vision for Chronic Kidney Disease: Sylvia Varela on Transforming CKD Care in Asia
- ACG Leads the Charge in Vegan Capsules: Innovation, Certification, and the Future of Sustainable Pharma
- ORA’s Hybrid Model Reshapes Obesity Care: Dr. Ben Ng on Bridging Telehealth and In-Person Treatment
- Heather Hargett on How Merck’s HUB Organoids Acquisition is Reshaping 3D Cell Culture and Drug Development
- Health2Sync's Vision for Diabetes Care: Transforming Outcomes Through Technology and Partnerships
Bio Jobs
- Ravindra Rao Joins GOBI Technologies as Director of Life Sciences – APAC
- Amgen Announces $900 Million Expansion of Ohio Biomanufacturing Facility, Boosting Investment to Over $1.4 Billion
- Thermo Fisher Scientific Appoints Former CVS Health CEO Karen S. Lynch to Board of Directors
- Merck KGaA Reshapes Leadership for the Future with Key Executive Moves
- Aarian Health Appoints Thomas Keller as Business Director to Drive Innovation and Growth
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
News
Editor Picks
